{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:44:28Z","timestamp":1785840268282,"version":"3.56.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.eprac.2026.03.093","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:29:24Z","timestamp":1774970964000},"page":"1203-1214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive Pharmacovigilance Assessment of Pegvisomant-Associated Adverse Events Using the FDA Adverse Event Reporting System and World Health Organization VigiAccess Databases"],"prefix":"10.1016","volume":"32","author":[{"given":"Kaizhi","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huqiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afang","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.eprac.2026.03.093_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2024.101910","article-title":"Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess","volume":"38","author":"MacFarlane","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.093_bib2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40618-017-0614-1","article-title":"Pegvisomant in acromegaly: an update","volume":"40","author":"Giustina","year":"2017","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.093_bib3","first-page":"2958","article-title":"Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs","volume":"85","author":"Herman-Bonert","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.093_bib4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"9","key":"10.1016\/j.eprac.2026.03.093_bib5","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.093_bib6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11102-024-01397-w","article-title":"Standards of care for medical management of acromegaly in Pituitary Tumor Centers of Excellence (PTCOE)","volume":"27","author":"Giustina","year":"2024","journal-title":"Pituitary"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.093_bib7","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1210\/jc.2010-0538","article-title":"A pegylated growth hormone receptor antagonist, pegvisomant, does not enter the brain in humans","volume":"95","author":"Veldhuis","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.093_bib8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/EJE-18-0616","article-title":"Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY","volume":"179","author":"Buchfelder","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.093_bib9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/EJE-21-0239","article-title":"More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY","volume":"185","author":"Fleseriu","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2026.03.093_bib10","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1210\/jc.2008-0833","article-title":"Lipodystrophy in patients with acromegaly receiving pegvisomant","volume":"93","author":"Bonert","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.eprac.2026.03.093_bib11","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/0003-4819-147-10-200711200-00019","article-title":"Pegvisomant-induced lipohypertrophy: report of a case with histopathology","volume":"147","author":"Marazuela","year":"2007","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.093_bib12","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40618-022-01980-7","article-title":"Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an european referral centre real-life experience","volume":"46","author":"Pirchio","year":"2023","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.093_bib13","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1210\/jc.2011-2508","article-title":"Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY","volume":"97","author":"van der Lely","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.093_bib14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4158\/EP14330.OR","article-title":"Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY","volume":"21","author":"Freda","year":"2015","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.093_bib15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11102-007-0042-x","article-title":"Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy","volume":"10","author":"Frohman","year":"2007","journal-title":"Pituitary"},{"key":"10.1016\/j.eprac.2026.03.093_bib16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12902-020-0545-2","article-title":"Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies","volume":"20","author":"Ma","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.eprac.2026.03.093_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103385","article-title":"Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data","volume":"86","author":"Wang","year":"2025","journal-title":"Eclinicalmedicine"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.093_bib18","first-page":"420","article-title":"A standardized dataset of a spontaneous adverse event reporting system","volume":"10","author":"Khaleel","year":"2022","journal-title":"Health Care (Don Mills)"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.093_bib19","doi-asserted-by":"crossref","first-page":"606","DOI":"10.4103\/0253-7613.190766","article-title":"Promoting public access to VigiBase","volume":"48","author":"Shankar","year":"2016","journal-title":"Indian J Pharmacol"},{"issue":"12","key":"10.1016\/j.eprac.2026.03.093_bib20","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s40264-018-0706-7","article-title":"A critical evaluation of safety signal analysis using algorithmic standardised MedDRA queries","volume":"41","author":"Tieu","year":"2018","journal-title":"Drug Saf"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.093_bib21","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.093_bib22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/life10080138","article-title":"Comparison of data mining methods for the signal detection of adverse drug events with a hierarchical structure in postmarketing surveillance","volume":"10","author":"Park","year":"2020","journal-title":"Life"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.093_bib23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.093_bib24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.093_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2023.102884","article-title":"Efficacy and safety of pegvisomant in the treatment of acromegaly","volume":"54","author":"Haberbosch","year":"2023","journal-title":"Arch Med Res"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.093_bib26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1507\/endocrj.EJ19-0266","article-title":"Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance","volume":"67","author":"Yamaguchi","year":"2020","journal-title":"Endocr J"},{"key":"10.1016\/j.eprac.2026.03.093_bib27","article-title":"Pegvisomant in managing comorbidities of acromegaly: a review","author":"Brue","year":"2025","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.eprac.2026.03.093_bib28","first-page":"47","article-title":"Profile of pegvisomant in the management of acromegaly: an evidence based review of its place in therapy","volume":"5","author":"Bernabeu","year":"2015","journal-title":"Res Rep Endocr Disord"},{"issue":"10","key":"10.1016\/j.eprac.2026.03.093_bib29","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40618-014-0146-x","article-title":"Use of pegvisomant in acromegaly. An Italian society of Endocrinology Guideline","volume":"37","author":"Giustina","year":"2014","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.093_bib30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12020-014-0462-0","article-title":"Optimal use of pegvisomant in acromegaly: are we getting there?","volume":"48","author":"Giustina","year":"2015","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.093_bib31","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s11102-022-01206-2","article-title":"Patient-Reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: a real-world experience","volume":"25","author":"Salvatori","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.eprac.2026.03.093_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1573721","article-title":"Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study","volume":"16","author":"Venegas Moreno","year":"2025","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.eprac.2026.03.093_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1266339","article-title":"Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly","volume":"14","author":"Clemmons","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.eprac.2026.03.093_bib34","doi-asserted-by":"crossref","DOI":"10.1210\/endrev\/bnaf020","article-title":"Medical treatment of acromegaly: navigating the present, shaping the future","author":"Gadelha","year":"2025","journal-title":"Endocr Rev"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.093_bib35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3390\/ijms26020465","article-title":"Differential impact of medical therapies for acromegaly on glucose metabolism","volume":"26","author":"Gatto","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.093_bib36","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1530\/EJE-08-0205","article-title":"Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials","volume":"159","author":"Jimenez","year":"2008","journal-title":"Eur J Endocrinol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26009171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26009171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:53:58Z","timestamp":1785837238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26009171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1530891X26009171"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.03.093","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive Pharmacovigilance Assessment of Pegvisomant-Associated Adverse Events Using the FDA Adverse Event Reporting System and World Health Organization VigiAccess Databases","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.03.093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}